Journal
CLINICAL IMMUNOLOGY
Volume 163, Issue -, Pages 22-33Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2015.12.005
Keywords
Experimental autoimmune encephalomyelitis; Multiple sclerosis; Semaphorin; Immune response; Neurodegeneration
Categories
Funding
- Spanish Ministry of Economy and Competitiveness by the Fondo de Investigacion Sanitaria (FIS)
- Institute de Salud Carlos III [PS09/01180]
- MINECO [SAF2009-07842, SAF2012-40023, ADE10-0010, RD07-0060-2007, RD12-0032-12]
- Fondation ARSEP (France, ARSEP-tPA/NMDA-MS)
- Fundacion Eugenio Rodriguez Pascual (Spain, FERP-POHTCMS)
- Red Espanola de Esclerosis Multiple (REEM) - FIS [RD07/0060, RD12/0032]
- Instituto de Salud Carlos III
- Ministry of Economy and Competitiveness in Spain
- Ajuts per donar Suport als Grups de Recerca de Catalunya - Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya in Spain [2009 SGR 0793, 2014 SGR 1082]
- PFIS programme of the Ministry of Economy and Competitiveness [FI10/00456]
- Sara Borrell programme of the FIS of the Ministry of Economy and Competitiveness of Spain [CD09/00363]
- Miguel Servet programme of the FIS of the Ministry of Economy and Competitiveness of Spain [CP07/00146, CP13/00028]
- MINECO FPI programme [SAF2009-07842, BES-2010-042593]
Ask authors/readers for more resources
We characterised the expression of semaphorin (sema)3A, sema7A and their receptors in the immune and the central nervous system (CNS) at different stages of experimental autoimmune encephalomyelitis (EAE). We also studied their expression in neonatal and adult oligodendrocyte progenitor cell (OPC) and in mature oligodendrocyte cultures. Our results show that sema3A is increased in the CNS and decreased in the immune system upon EAE induction. However, sema7A expression is increased in both the CNS and the immune system during EAE. We also detected sema3A, sema7A and their receptors in neonatal and adult OPCs and in mature oligodendrocytes. These data suggest that sema3A and sema7A are involved in the pathogenesis of EAE, in the modulation of the immune response and in the neurodegeneration that take place in the CNS. Sema7A may represent an intriguing potential therapeutic target for the treatment of both the neurodegenerative and immune-mediated disease processes in MS. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available